Back | Next |
home / stock / nspr / nspr message board
Subject | By | Source | When |
---|---|---|---|
INSATIABLE DUMPING | Disquisition | investorshub | 07/02/2021 2:35:20 PM |
some conference today, looks like 'someone' likes what | timberwolf7 | investorshub | 06/09/2021 7:23:48 PM |
UNIMAGINABLE DUMPING | Disquisition | investorshub | 06/03/2021 8:01:20 PM |
UNREAL DUMPING | Disquisition | investorshub | 05/28/2021 11:07:26 PM |
whytestocks: $NSPR News Article - InspireMD Commences Trading on Nasdaq-CM | whytestocks | investorshangout | 05/21/2021 3:00:47 PM |
DESPICABLE DUMPING | Disquisition | investorshub | 05/12/2021 8:07:09 PM |
UNCOMPROMISING DUMPING | Disquisition | investorshub | 05/11/2021 5:05:54 PM |
REMORSELESS DUMPING | Disquisition | investorshub | 05/10/2021 1:31:14 PM |
INCOMPREHENSIBLE DUMPING | Disquisition | investorshub | 05/06/2021 5:47:12 PM |
UNRELENTING DUMPING | Disquisition | investorshub | 05/04/2021 5:03:56 PM |
INDEFATIGABLE DUMPING | Disquisition | investorshub | 05/03/2021 3:06:32 PM |
ALL OVER THIS GARBAGE DILUTION MACHINE | Disquisition | investorshub | 04/30/2021 12:51:23 PM |
* * $NSPR Video Chart 04-27-2021 * * | ClayTrader | investorshub | 04/27/2021 10:28:34 PM |
Where? | stock1ace1 | investorshub | 04/27/2021 2:46:39 PM |
whytestocks: $NSPR News Article - NSPR Stock: What You Should Know About InspireMD Today | whytestocks | investorshangout | 04/27/2021 2:20:47 PM |
COLOSSAL DUMPING | Disquisition | investorshub | 04/27/2021 9:53:32 AM |
Weeeeeeee!! | iluvkush | investorshub | 04/27/2021 8:36:08 AM |
znewcar1: CSPR 27% v15,7M c8.95 f40,5M H9.29 | znewcar1 | investorshangout | 04/26/2021 8:50:47 PM |
well at least we knew it was coming | pzottkpz | investorshub | 04/15/2021 9:55:15 PM |
Ohh there will be an offering at the | ErnieBilco | investorshub | 04/15/2021 3:19:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...
- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2...